Ignite Creation Date:
2024-05-06 @ 8:19 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06336395
Status:
RECRUITING
Last Update Posted:
2024-03-28
First Post:
2024-03-21
Brief Title:
Ma-Spore ALL 2020 Study
Sponsor:
National University Hospital Singapore
Organization:
National University Hospital Singapore
Study Overview
Official Title:
Ma-Spore ALL-Seq 2020 RNA-Seq and IgHTCR-Seq to Improve Risk Assignment in Childhood Adolescent and Young Adult Acute Lymphoblastic Leukaemia
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this trial is to improve the overall survival rate of children and young adult with B-lineage acute lymphoblastic leukemia B-ALL in Singapore and Malaysia in the context of a multicenter cooperative trial using a risk-stratified therapy
Detailed Description:
This is a multicenter open-label phase II study involving children and young adult 41 years old who are newly diagnosed with B-ALL and treatment naïve There will be 3 parallel cohorts whose risk to be stratified based upon leukemia genetics profiles and patients treatment response
1 Standard Risk SR
2 Intermediate Risk IR
3 High Risk HR
All drugs being used are commercially available chemotherapy drugs There will be no novel chemotherapeutic agent without marketing authorization being tested in this trial
1 Standard Risk SR
2 Intermediate Risk IR
3 High Risk HR
All drugs being used are commercially available chemotherapy drugs There will be no novel chemotherapeutic agent without marketing authorization being tested in this trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None